Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks

Chinese Journal of Cancer

Volumn 31, Issue 8, 2012, Pages 373-380

  Liu, Xiao Jun ^a   Nowak, Billie ^a   Wang, Ya Qing ^a,b   Plunkett, William ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

Author keywords

CNDAC; Cytarabine; Gemcitabine; Homologous recombination; Sapacitabine

Indexed keywords

CYTARABINE; GEMCITABINE; RAD51 PROTEIN; RAD51D PROTEIN; SAPACITABINE; UNCLASSIFIED DRUG; XRCC3 PROTEIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLONOGENESIS; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPAIR; DNA STRAND BREAKAGE; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; HAMSTER; HOMOLOGOUS RECOMBINATION; IC 50; NONHUMAN; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOSIDES; CHO CELLS; CRICETINAE; CRICETULUS; CYTARABINE; CYTOSINE; DEOXYCYTIDINE; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; HOMOLOGOUS RECOMBINATION; INHIBITORY CONCENTRATION 50; PRODRUGS;

EID: 84865222487     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10077     Document Type: Article

References (29)

1. Liu X, Kantarjian H, Plunkett W. Sapacitabine for cancer. Expert Opin Investig Drugs, 2012,21:541-555.
2. Ghaddar HM, Plunkett W, Kantarjian HM, et al. Long te rm results following treatment of newly diagnosed acute myelogenous leukemia with continuous in fusion high dose cytosine arabinoside. Leukemia, 1994,8:1269-1274.
3. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine(2',2' difluoro 2' deoxy cytidine). Cancer Res, 1990,50:4417-4422.
4. Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol, 1994,12:1527-1531.
5. Hanaoka K, Suzuki M, Kobayashi T, et al. Antitumor activity and novel DNA s elf st rand breaking mechanism of CNDAC (1 (2 C c yano 2 deoxy beta D ar abino pentofuranosyl)cytosine) and its N4 palmitoyl derivative (CS 682). Int J Cancer, 1999,82: 226-236.
6. Sapacitabine, cyclophosphamide, rituximab for relapsed chronic lymphocytic leukemia, small lymphocytic lymphoma (CLL/SLL) with deletion (11q22 23). ClinicalTrials.gov, Identifier: NCT01253460.
7. A study of oral sapacitabine in elderly patients with newlydiagnosed acute myeloid leukemia (SEAMLESS). ClinicalTrials. gov, Identifier: NCT01303796.
8. Study of sapacitabine in acute myeloid leukemia (AML).ClinicalTrials.gov, Identifier: NCT01211457.
9. A study of oral sapacitabine and oral seliciclib in patients withadvanced solid tumors. ClinicalTrials.gov, Identifier: NCT00 999401.
10. Efficacy study of oral sapacitabine to treat acute myeloid leukemia in elderly patients. ClinicalTrials.gov, Identifier: NCT00590187.
11. A study of oral sapacitabine in patients with previously treated non s mall cell lung cancer. ClinicalTrials.gov, Identifier: NCT00885963.
12. Safety and pharmacology study of sapacitabine to treat advanced leukemias or myelodysplastic syndromes. ClinicalTrials.gov, Identifier: NCT00380653.
13. A randomized phase II study of oral sapacitabine in patients with advanced cutaneous T cell lymphoma. ClinicalTrials.gov, Identifier: NCT00476554.
14. Delaunoit T, Burch PA, Reid JM, et al. A phase IL clinical and pharmacokinetic study of CS 682 administered orally in advanced malignant solid tumors. Invest New Drugs, 2006,24: 327-333.
15. Gilbert J, Carducci MA, Baker SD, et al. A phase I study of the oral antimetabolite, CS 682, administered once daily 5 days per week in patients with refractory solid tumor malignancies. Invest New Drugs, 2006,24:499-508.
16. Kantarjian H, Garcia and #x9104;M anero G, O'Brien S, et al. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol, 2010,28:285-291.
17. Matsuda A, Nakajima Y, Azuma A, et al. Nucleosides and nucleotides. 100. 2' C c yano 2' deoxy 1 beta D a rabinofuranosyl cytosine(CNDAC): design of a potential mechanism based DNA s trand breaking antineoplastic nucleoside. J Med Chem, 1991,34:2917-2919.
18. Wang Y, Liu X, Matsuda A, et al. Repair of 2' C cyano 2' deoxy 1 beta D arabino pentofuranosylcytosine in duced DNA single st rand breaks by transcription coupled nucleotide excision repair. Cancer Res, 2008,68:3881-3889.
19. Liu X, Wang Y, Benaissa S, et al. Homologous recombination as a resistance mechanism to replication in duced double strand breaks caused by the antileukemia agent CNDAC. Blood, 2010,116:1737-1746.
20. Tebbs RS, Zhao Y, Tucker JD, et al. Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene. Proc Natl Acad Sci U S A, 1995,92:6354-6358.
21. Hinz JM, Tebbs RS, Wilson PF, et al. Repression of mutagenesis by Rad51D m ediated homologous recombination. Nucleic Acids Res, 2006,34:1358-1368.
22. Shi Z, Azuma A, Sampath D, et al. S phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7 hydroxystaurosporine. Cancer Res, 2001,61:1065-1072.
23. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine: metabolism, mechanisms of action, and self potentiation. Semin Oncol, 1995,22:3-10.
24. Schafer A, Schomacher L, Barreto G, et al. Gemcitabine functions epigenetically by inhibiting repair mediated DNA demethylation. PLoS One, 2010,5:e14060.
25. Azuma A, Huang P, Matsuda A, et al. 2' C c yano 2' deoxy 1 beta D arabino pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G2 arrest. Mol Pharmacol, 2001,59:725-731.
26. Al and #x9104;M inawi AZ, Lee YF, Hakansson D, et al. The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter s trand cross lin ks. Nucleic Acids Res, 2009,37:6400-6413.
27. Ravandi F, Faderl S, Cortes JE, et al. Phase I/II study of sapacitabine and decitabine administered sequentially in elderly patients with newly diagnosed acute myeloid leukemia. ASCO Meeting Abstracts, 2011,29:6587.
28. Fordham SE, Matheson EC, Scott K, et al. DNA mismatch repair status affects cellular response to Ara C and other anti leukemic nucleoside analogs. Leukemia, 2011,25:1046-1049.
29. Crul M, van Waardenburg RC, Bocxe S, et al. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol, 2003,65:275-282.